IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES IDIQ CONTRACT. POP 9/27/21-9/26/26. NTE $3.5 MILLION. TASK ORDER 03 OBLIGATED IN THE AMOUNT OF $136

体外代谢和非临床 ADME 研究 IDIQ 合同。

• 批准号: 10710585
• 负责人: MARY BASTIDA
• 金额: $ 16.57万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-27 至 2026-09-26
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10710585
• 关键词: ADME Study; Contracts; Data; Development; Drug Addiction; Evaluation; In Vitro; Investigational Drugs; Medical; Metabolism; National Institute of Drug Abuse; Permeability; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology and Toxicology; Program Development; Research Personnel; Research Support; Therapeutic; United States Food and Drug Administration; addiction; in vivo; novel therapeutics; research and development; research clinical testing

The Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA) supports research and development of new medications for the treatment of drug addiction. Medication development involves in vitro evaluations, nonclinical pharmacology and toxicology studies, pharmaceutical development, and clinical evaluation of new medications for treating addiction.

国家药物滥用研究所（NIDA）治疗和医学后果司（DTMC） 支持研究和开发治疗毒瘾的新药物。药物开发 涉及体外评价、非临床药理学和毒理学研究、药物开发，以及 治疗成瘾的新药物的临床评价。